1. Epigenetics
    TGF-beta/Smad
  2. PKC

Ruboxistaurin hydrochloride (Synonyms: LY 333531 hydrochloride)

Cat. No.: HY-10195B Purity: 99.54%
Data Sheet SDS Handling Instructions

Ruboxistaurin hydrochloride is a isozyme-selective inhibitor of protein kinase C (PKC), a competitive reversible inhibitors of PKCβI and PKCβII with IC50 value of 4.7 nM and 5.9 nM respectivily.

For research use only. We do not sell to patients.
Ruboxistaurin hydrochloride Chemical Structure

Ruboxistaurin hydrochloride Chemical Structure

CAS No. : 169939-93-9

Size Price Stock Quantity
10 mM * 1 mL in DMSO $211 In-stock
1 mg $50 In-stock
5 mg $190 In-stock
10 mg $350 In-stock
25 mg $750 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Ruboxistaurin hydrochloride is a isozyme-selective inhibitor of protein kinase C (PKC), a competitive reversible inhibitors of PKCβI and PKCβII with IC50 value of 4.7 nM and 5.9 nM respectivily. target: PKC β1/β2 [1] IC50: 4.7 ( PKCβI ), 5.9 nM ( PKCβII ) In vivo: A significant up-regulation of TGF-b1, Smad2 and Smad3 mRNA expression was observed in diabetic rats, which was alleviated by administration of ruboxistaurin.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT00044148 Chromaderm, Inc. Diabetic Nephropathy July 16, 2002 Phase 2
NCT02769611 Children's Hospital Medical Center, Cincinnati|The Christ Hospital Heart Failure August 2016 Phase 1|Phase 2
NCT00190970 Chromaderm, Inc. Diabetic Neuropathy October 2004 Phase 2
NCT00133952 Chromaderm, Inc. Diabetic Macular Edema August 2005 Phase 3
NCT00604383 Chromaderm, Inc. Diabetic Retinopathy March 2001 Phase 3
NCT00266695 Chromaderm, Inc. Diabetic Retinopathy January 2006 Phase 3
NCT00297401 Chromaderm, Inc.|Heart and Stroke Foundation of Canada Diabetes Mellitus, Type 1 March 2006 Phase 3
NCT00761852 Brigham and Women's Hospital|Eli Lilly and Company Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus May 1999 Phase 2|Phase 3
NCT00552227 Chromaderm, Inc. Diabetes Mellitus September 2002 Phase 1
NCT00482976 Chromaderm, Inc.|Joslin Diabetes Center Diabetes Mellitus December 2003 Phase 2
NCT00090519 Chromaderm, Inc. Diabetic Retinopathy February 2004 Phase 3
NCT00044408 Chromaderm, Inc. Diabetic Neuropathies|Diabetes Mellitus, Insulin-Dependent|Diabetes Mellitus, Non-Insulin-Dependent July 2002 Phase 3
NCT00044421 Eli Lilly and Company Diabetic Neuropathies|Diabetes Mellitus July 2002 Phase 3
NCT00044395 Eli Lilly and Company Diabetic Neuropathies|Diabetes Mellitus, Insulin-Dependent|Diabetes Mellitus, Non-Insulin-Dependent July 2002 Phase 3
View MoreCollapse
References
Molecular Weight

505.01

Formula

C₂₈H₂₉ClN₄O₃

CAS No.

169939-93-9

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 6.8 mg/mL (Need ultrasonic and warming)

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ruboxistaurin hydrochloride
Cat. No.:
HY-10195B
Quantity: